This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sony Corporation Adopts Kaneka Corporation's Foam Molded Product Made from Kaneka Biodegradable Polymer Green Planet as A Cushioning Material for Its Large-Screen Televisions CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on February 8, 2024. CI
Kaneka Corporation announces an Equity Buyback for 2,000,000 shares, representing 3.08% for ¥8,000 million. CI
Kaneka Corporation authorizes a Buyback Plan. CI
Kaneka Corporation acquired Japan Medical Device Technology Co., Ltd. CI
Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches MT
Kaneka Corporation Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation's Equity Buyback announced on September 9, 2022 has closed with 2,300,000 shares, representing 3.47% for ¥8,042.21 million. CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation Announces Manufacture and Supply Intermediates to Shionogi & Co., Ltd for Use in Xocova® CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million. CI
Kaneka Corporation authorizes a Buyback Plan. CI
Kaneka Corporation agreed to acquire remaining 45.24% stake in Cemedine Co., Ltd.. CI
Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) Variants CI
Kaneka Corporation to Significantly Increase Its Production Capacity for Kaneka Biodegradable Polymer Green Planet™ in Japan CI
Banners, lights as Japan hails MVP award for baseballer Ohtani RE
Kaneka Releases PCR Test Kit for COVID-19 Variants CI
Kaneka : Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka RE
Denka : Japan to extend foreign investment controls to Avigan suppliers - Yomiuri RE
Kaneka Corporation Agrees to Supply Active Pharmaceutical Ingredients for Avigan Tablet CI
Kaneka Corporation Announces Consolidated Financial Results for the Nine Months Ended December 31, 2019; Provides Consolidated Financial Guidance for the Year Ending March 31, 2020 CI
Kaneka Corporation(TSE:4118) dropped from S&P Japan Mid Cap 100 CI
Kaneka Corporation Reports Consolidated Earnings Results for the Year Ended March 31, 2019 CI
Chart Kaneka Corporation
More charts
KANEKA CORPORATION is a Japan-based company engaged in four business segments. The Material Solutions Unit segment includes general purpose vinyl chloride resin, caustic soda, polyvinyl chloride special resin, modifier, modified silicone polymer, biodegradable polymer. Quality of Life Solutions Unit segment includes expanded styrene resin and molded products, extruded polystyrene foam boards, bead method expanded polyolefin, solar circuit method, super heat resistant polyimide films, optical materials, super heat conductive graphite sheets, solar cells, storage batteries for housing and others. The Health Care Solutions Unit segment includes medical devices, low molecular weight pharmaceutical raw materials, biopharmaceuticals, etc. The Nutrition Solutions Unit segment includes functional food ingredients, margarine, shortening, baker's yeast, spices, antifreeze ingredients, functional fertilizers and feeds.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3,990 JPY
Average target price
4,091 JPY
Spread / Average Target
+2.54%
Consensus
  1. Stock Market
  2. Equities
  3. 4118 Stock
  4. News Kaneka Corporation
  5. Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches